References
- Adjei AA (2001): Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062–1074.
- Bourguet-Kondracki MIL, Martin MT, Debitus C, Guyot M (1994): 12-epi-Heteronemin: New sesterterpene from the marine sponge Hyrtios erecta. Tetrahedron Lett 35: 109–110.
- Cohen LH, Pieterman E, van Leeuxen REW, Overhand M, Burm BEA, van der Marel GA, van Boom JH (2000): Inhibitors of prenylation of Ras and other G-proteins and their appli-cation as therapeutics. Biochem Pharmacol 60: 1061–1068.
- Hill BT, Perrin D, Kruczynski A (2000): Inhibiton of RAS-targeted prenylation: Protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 33: 7–23.
- Kazlauskas R, Murphy PT, Quinn RJ, Wells RJ (1976): Het-eronemin, a new scalarin type sesterpene from the sponge Heteronema erecta. Tetrahedron Lett 30: 2631–2634.
- Prendergast GC (2000): Farnesyltransferase inhibitors: Anti-neoplasic mechanism and clinical prospects. Curr Opin Cell Biol 12: 166–173.
- Sangkyou L, Seyeon P, Jae-Wook O, Chul-hakY. (1998): Natural inhibitors for protein prenyltransferase. Planta Med 64: 303–308.
- Sebti SM, Hamilton AD (2000): Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues. Exp Opin Invest Drugs 9: 2767–2782.